Atyr Pharma Inc (NASDAQ: LIFE) is 43.26% higher on its value in year-to-date trading and has touched a low of $1.08 and a high of $2.70 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The LIFE stock was last observed hovering at around $2.02 in the last trading session, with the day’s loss setting it 0.0%.
Currently trading at $2.02, the stock is 11.25% and 16.12% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.89 million and changing 0.00% at the moment leaves the stock 20.78% off its SMA200. LIFE registered 4.12% gain for a year compared to 6-month gain of 24.69%. The firm has a 50-day simple moving average (SMA 50) of $150.44 and a 200-day simple moving average (SMA200) of -$1.02.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 2.54% loss in the last 1 month and extending the period to 3 months gives it a 44.29%, and is 24.69% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 11.57% over the week and 7.54% over the month.
Atyr Pharma Inc (LIFE) has around 59 employees, a market worth around $136.85M and $0.35M in sales. Profit margin for the company is -14274.50%. Distance from 52-week low is 87.02% and -25.18% from its 52-week high. The company has generated returns on investments over the last 12 months (-48.25%).
Atyr Pharma Inc quarterly earnings per share for the current quarter are estimated at -$0.24 with sales reaching $20k over the same period.The EPS is expected to shrink by -0.43% this year, but quarterly earnings will post 511.90% year-over-year. Quarterly sales are estimated to shrink -93.30% in year-over-year returns.
58 institutions hold shares in Atyr Pharma Inc (LIFE), with institutional investors hold 63.37% of the company’s shares. The shares outstanding are 67.75M, and float is at 65.34M with Short Float at 0.17%. Institutions hold 61.92% of the Float.
The top institutional shareholder in the company is Federated Hermes, Inc. with over 10.19 million shares valued at $22.01 million. The investor’s holdings represent 17.86% of the LIFE Shares outstanding. As of Jun 29, 2023, the second largest holder is FMR, LLC with 8.14 million shares valued at $17.59 million to account for 14.28% of the shares outstanding. The other top investors are Stonepine Capital Management, LLC which holds 4.63 million shares representing 8.11% and valued at over $9.99 million, while Tikvah Management LLC holds 4.31% of the shares totaling 2.46 million with a market value of $5.32 million.
Atyr Pharma Inc (LIFE) Insider Activity
The most recent transaction is an insider sale by Broadfoot Jill Marie, the company’s Chief Financial Officer. SEC filings show that Broadfoot Jill Marie sold 1,590 shares of the company’s common stock on Feb 06 ’24 at a price of $1.69 per share for a total of $2687.0. Following the sale, the insider now owns 20821.0 shares.
Atyr Pharma Inc disclosed in a document filed with the SEC on Dec 12 ’23 that Shukla Sanjay (President and CEO) bought a total of 12,000 shares of the company’s common stock. The trade occurred on Dec 12 ’23 and was made at $1.18 per share for $14136.0. Following the transaction, the insider now directly holds 0.11 million shares of the LIFE stock.
Still, SEC filings show that on Dec 11 ’23, Shukla Sanjay (President and CEO) acquired 3,000 shares at an average price of $1.17 for $3510.0. The insider now directly holds 94,173 shares of Atyr Pharma Inc (LIFE).
